KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Total Debt (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Total Debt data on record, last reported at $2.1 billion in Q4 2025.

  • For Q4 2025, Total Debt fell 5.69% year-over-year to $2.1 billion; the TTM value through Dec 2025 reached $2.1 billion, down 5.69%, while the annual FY2025 figure was $2.1 billion, 5.69% down from the prior year.
  • Total Debt reached $2.1 billion in Q4 2025 per CRL's latest filing, down from $2.2 billion in the prior quarter.
  • Across five years, Total Debt topped out at $3.0 billion in Q2 2022 and bottomed at $2.1 billion in Q4 2025.
  • Average Total Debt over 5 years is $2.6 billion, with a median of $2.7 billion recorded in 2023.
  • Peak YoY movement for Total Debt: surged 34.68% in 2021, then fell 14.46% in 2023.
  • A 5-year view of Total Debt shows it stood at $2.7 billion in 2021, then increased by 1.54% to $2.7 billion in 2022, then dropped by 2.23% to $2.6 billion in 2023, then fell by 14.43% to $2.3 billion in 2024, then decreased by 5.69% to $2.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $2.1 billion in Q4 2025, $2.2 billion in Q3 2025, and $2.3 billion in Q2 2025.